New contrast agents for magnetic resonance imaging are continually being de
veloped by pharmaceutical companies in order to better image the liver. The
se agents can be divided into hepatobiliary agents directed to the hepatocy
tes and nanoparticulate agents directed to the reticulo-endothelial system.
After intravenous injection, all these agents concentrate in the liver and
induce profound changes in signal intensity. Particulate agents induce pre
dominantly a darkening of the liver parenchyma, while hepatobiliary agents
induce a brightening. In both cases, liver-lesion conspicuity is enhanced,
leading to a better visualization of the lesion.
After a brief description of the principal characteristics of the agents, t
his paper will attempt to summarize the utility of these agents for the det
ection and characterization of focal liver disease.